Capsaicin enhances anti-proliferation efficacy of pirarubicin via activating TRPV1 and inhibiting PCNA nuclear translocation in 5637 cells

Zheng,Long; Chen,Jiaqi; Ma,Zhenkun; Liu,Wei; Yang,Fei; Yang,Zhao; Wang,Ke; Wang,Xinyang; He,Dalin; Li,Lei; Zeng,Jin

doi:10.3892/mmr.2015.4623

Capsaicin enhances anti-proliferation efficacy of pirarubicin via activating TRPV1 and inhibiting PCNA nuclear translocation in 5637 cells

Authors:
- Long Zheng
- Jiaqi Chen
- Zhenkun Ma
- Wei Liu
- Fei Yang
- Zhao Yang
- Ke Wang
- Xinyang Wang
- Dalin He
- Lei Li
- Jin Zeng
View Affiliations

Affiliations: Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi 710061, P.R. China
Published online on: November 30, 2015 https://doi.org/10.3892/mmr.2015.4623
Pages: 881-887

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The recurrence of bladder cancer after surgery with or without chemotherapy remains a major challenge in bladder cancer treatment. Previous studies have shown that transient receptor potential vanilloid 1 (TRPV1) acts as a tumor suppressor through inducing apoptosis in bladder cancer cells. However, whether activation of TRPV1 has any synergistic effects with pirarubicin (THP), one of main drugs used in urinary bladder instillation chemotherapy to improve chemotherapeutic efficacy has remained elusive. The present study verified that TRPV1 was differentially expressed in bladder cancer cell lines. Furthermore, activation of TRPV1 by capsaicin was shown to induce growth inhibition of 5637 cells in which TRPV1 was highly expressed, while the growth of T24 cells, which express TRPV1 at low levels, was not affected. In addition, the present study demonstrated that activation of TRPV1 enhanced the anti‑proliferative effects of pirarubicin using an MTT assay and cell cycle analysis. Finally, immunofluorescent microscopy revealed that activation of TRPV1 prevented the translocation of proliferating cell nuclear antigen to the nucleus. This phenomenon was reversed by pre‑treatment with capsazepine, a specific TRPV1 antagonist. In conclusion, the present study confirmed the anti‑tumor activity of TRPV1 against bladder cancer. Activation of TRPV1 may be applied as a novel strategy to treat bladder cancer or enhance the therapeutic efficacy of traditional chemotherapeutic drugs.

View Figures

View References

1	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA A Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar
2	Cookson MS, Chang SS, Lihou C, Li T, Harper SQ, Lang Z and Tutrone RF: Use of intravesical valrubicin in clinical practice for treatment of nonmuscle-invasive bladder cancer, including carcinoma in situ of the bladder. Ther Adv Urol. 6:181–191. 2014. View Article : Google Scholar : PubMed/NCBI
3	Kamat AM and Lamm DL: Antitumor activity of common antibiotics against superficial bladder cancer. Urology. 63:457–460. 2004. View Article : Google Scholar : PubMed/NCBI
4	Arakawa M, Nakamura K, Yamada Y, Kato K, Katsuda R, Tobiume M, Zennami K, Watanabe M, Kato Y, Nishikawa G, et al: Intravesical administration of pirarubicin against superficial bladder cancer: Relationship between tumor tissue concentration and exposure time in the bladder or therapeutic effect. Exp Ther Med. 2:901–905. 2011.
5	Fukushima T, Ueda T and Nakamura T: Pharmacokinetics and action mechanism of anthracyclines. Jpn J Cancer Chemother. 19:445–450. 1992.In Japanese.
6	Miki T, Nonomura N, Kojima Y, Okuyama A, Nakano E, Kiyohara H, Fujioka H, Koide T, Wakatsuki A, Kuroda H, et al: A randomized study on intravesical pirarubicin (THP) chemoprophylaxis of recurrence after transurethral resection of superficial bladder cancer. Acta Urol Jpn. 43:907–912. 1997.In Japanese.
7	Zhou J, Zhang X, Li M, Wu W, Sun X, Zhang L and Gong T: Novel lipid hybrid albumin nanoparticle greatly lowered toxicity of pirarubicin. Mol Pharm. 10:3832–3841. 2013. View Article : Google Scholar : PubMed/NCBI
8	Cao E, Cordero-Morales JF, Liu B, Qin F and Julius D: TRPV1 channels are intrinsically heat sensitive and negatively regulated by phosphoinositide lipids. Neuron. 77:667–679. 2013. View Article : Google Scholar : PubMed/NCBI
9	Ho KW, Ward NJ and Calkins DJ: TRPV1: A stress response protein in the central nervous system. Am J Neurodegener Dis. 1:1–14. 2012.PubMed/NCBI
10	Avelino A and Cruz F: TRPV1 (vanilloid receptor) in the urinary tract: Expression, function and clinical applications. Naunyn Schmiedebergs Arch Pharmacol. 373:287–299. 2006. View Article : Google Scholar : PubMed/NCBI
11	Lazzeri M, Vannucchi MG, Spinelli M, Bizzoco E, Beneforti P, Turini D and Faussone-Pellegrini MS: Transient receptor potential vanilloid type 1 (TRPV1) expression changes from normal urothelium to transitional cell carcinoma of human bladder. Eur Urol. 48:691–698. 2005. View Article : Google Scholar : PubMed/NCBI
12	Vercelli C, Barbero R, Cuniberti B, Racca S, Abbadessa G, Piccione F and Re G: Transient receptor potential vanilloid 1 expression and functionality in mcf-7 cells: A preliminary investigation. J Breast Cancer. 17:332–338. 2014. View Article : Google Scholar : PubMed/NCBI
13	Wu TT, Peters AA, Tan PT, Roberts-Thomson SJ and Monteith GR: Consequences of activating the calcium-permeable ion channel TRPV1 in breast cancer cells with regulated TRPV1 expression. Cell Calcium. 56:59–67. 2014. View Article : Google Scholar : PubMed/NCBI
14	Stock K, Kumar J, Synowitz M, Petrosino S, Imperatore R, Smith ES, Wend P, Purfürst B, Nuber UA, Gurok U, et al: Neural precursor cells induce cell death of high-grade astrocytomas through stimulation of TRPV1. Nat Med. 18:1232–1238. 2012. View Article : Google Scholar : PubMed/NCBI
15	Mistretta F, Buffi NM, Lughezzani G, Lista G, Larcher A, Fossati N, Abrate A, Dell'Oglio P, Montorsi F, Guazzoni G and Lazzeri M: Bladder cancer and urothelial impairment: The role of TRPV1 as potential drug target. Biomed Res Int. 2014:9871492014. View Article : Google Scholar : PubMed/NCBI
16	Amantini C, Ballarini P, Caprodossi S, Nabissi M, Morelli MB, Lucciarini R, Cardarelli MA, Mammana G and Santoni G: Triggering of transient receptor potential vanilloid type 1 (TRPV1) by capsaicin induces Fas/CD95-mediated apoptosis of urothelial cancer cells in an ATM-dependent manner. Carcinogenesis. 30:1320–1329. 2009. View Article : Google Scholar : PubMed/NCBI
17	Santoni G, Caprodossi S, Farfariello V, Liberati S, Gismondi A and Amantini C: Antioncogenic effects of transient receptor potential vanilloid 1 in the progression of transitional urothelial cancer of human bladder. ISRN Urol. 2012:4582382012.PubMed/NCBI
18	Sanchez MG, Sanchez AM, Collado B, Malagarie-Cazenave S, Olea N, Carmena MJ, Prieto JC and Diaz-Laviada II: Expression of the transient receptor potential vanilloid 1 (TRPV1) in LNCaP and PC-3 prostate cancer cells and in human prostate tissue. Eur J Pharmacol. 515:20–27. 2005. View Article : Google Scholar : PubMed/NCBI
19	Costa MA, Fonseca BM, Keating E, Teixeira NA and Correia-da-Silva G: Transient receptor potential vanilloid 1 is expressed in human cytotrophoblasts: Induction of cell apoptosis and impairment of syncytialization. Int J Biochem Cell Biol. 57:177–185. 2014. View Article : Google Scholar : PubMed/NCBI
20	Lang H, Li Q, Yu H, Li P, Lu Z, Xiong S, Yang T, Zhao Y, Huang X, Gao P, et al: Activation of TRPV1 attenuates high salt-induced cardiac hypertrophy through improvement of mitochondrial function. Br J Pharmacol. Oct 23–2014.Epub ahead of print. PubMed/NCBI
21	Coelho A, Wolf-Johnston AS, Shinde S, Cruz CD, Cruz F, Avelino A and Birder LA: Urinary bladder inflammation induces Changes in urothelial nerve growth factor and TRPV1 channels. Br J Pharmacol. 172:1691–1699. 2015. View Article : Google Scholar
22	Kizek R, Adam V, Hrabeta J, Eckschlager T, Smutny S, Burda JV, Frei E and Stiborova M: Anthracyclines and ellipticines as DNA-damaging anticancer drugs: Recent advances. Pharmacol Ther. 133:26–39. 2012. View Article : Google Scholar
23	Zheng SE, Xiong S, Lin F, Qiao GL, Feng T, Shen Z, Min DL, Zhang CL and Yao Y: Pirarubicin inhibits multidrug-resistant osteosarcoma cell proliferation through induction of G2/M phase cell cycle arrest. Acta Pharmacol Sin. 33:832–838. 2012. View Article : Google Scholar : PubMed/NCBI
24	Takimoto CH and Calvo E: Principles of oncologic pharmacotherapy. Cancer Management: A Multidisciplinary Approach. 11:2008.
25	Garcia RL, Coltrera MD and Gown AM: Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fixed, embedded tissues. Comparison with flow cytometric analysis. Am J Pathol. 134:733–739. 1989.PubMed/NCBI
26	Bravo R, Frank R, Blundell PA and Macdonald-Bravo H: Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta. Nature. 326:515–517. 1987. View Article : Google Scholar : PubMed/NCBI
27	Kelman Z: PCNA: Structure, functions and interactions. Oncogene. 14:629–640. 1997. View Article : Google Scholar : PubMed/NCBI
28	Kalogris C, Caprodossi S, Amantini C, Lambertucci F, Nabissi M, Morelli MB, Farfariello V, Filosa A, Emiliozzi MC, Mammana G and Santoni G: Expression of transient receptor potential vanilloid-1 (TRPV1) in urothelial cancers of human bladder: Relation to clinicopathological and molecular parameters. Histopathology. 57:744–752. 2010. View Article : Google Scholar : PubMed/NCBI
29	Chen D, Yang Z, Wang Y, Zhu G and Wang X: Capsaicin induces cycle arrest by inhibiting cyclin-dependent-kinase in bladder carcinoma cells. Int J Urol. 19:662–668. 2012. View Article : Google Scholar : PubMed/NCBI
30	Gilardini Montani MS, D'Eliseo D, Cirone M, Di Renzo L, Faggioni A, Santoni A and Velotti F: Capsaicin-mediated apoptosis of human bladder cancer cells activates dendritic cells via CD91. Nutrition. 31:578–581. 2015. View Article : Google Scholar
31	D'Eliseo D, Manzi L and Velotti F: Capsaicin as an inducer of damage-associated molecular patterns (DAMPs) of immunogenic cell death (ICD) in human bladder cancer cells. Cell Stress Chaperones. 18:801–808. 2013. View Article : Google Scholar : PubMed/NCBI
32	Hartwell LH and Kastan MB: Cell cycle control and cancer. Science. 266:1821–1828. 1994. View Article : Google Scholar : PubMed/NCBI
33	Graña X and Reddy EP: Cell cycle control in mammalian cells: Role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene. 11:211–219. 1995.PubMed/NCBI
34	Li Q, Wang XH, Yang ZH, Wang HP, Yang ZW, Li SW and Zheng XM: Induction of cell cycle arrest in bladder cancer RT4 cells by capsaicin. Chin Med J. 90:1230–1233. 2010.In Chinese.
35	Mori A, Lehmann S, O'Kelly J, Kumagai T, Desmond JC, Pervan M, McBride WH, Kizaki M and Koeffler HP: Capsaicin, a component of red peppers, inhibits the growth of androgen-independent, p53 mutant prostate cancer cells. Cancer Res. 66:3222–3229. 2006. View Article : Google Scholar : PubMed/NCBI
36	Bunch RT and Eastman A: 7-Hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S-phase arrest in Chinese hamster ovary cells. Cell Growth Differ. 8:779–788. 1997.PubMed/NCBI
37	Koundrioukoff S, Jónsson ZO, Hasan S, de Jong RN, van der Vliet PC, Hottiger MO and Hübscher U: A direct interaction between proliferating cell nuclear antigen (PCNA) and Cdk2 targets PCNA-interacting proteins for phosphorylation. J Biol Chem. 275:22882–22887. 2000. View Article : Google Scholar : PubMed/NCBI
38	Moldovan GL, Pfander B and Jentsch S: PCNA controls establishment of sister chromatid cohesion during S phase. Mol Cell. 23:723–732. 2006. View Article : Google Scholar : PubMed/NCBI
39	Yoshikawa H, Ikeuchi T and Kai Y: Immunohistochemical study of the proliferating ability and malignant potential of transitional cell carcinoma in the human urinary bladder. Int J Urol. 3(Suppl 1): S32–S34. 1996. View Article : Google Scholar : PubMed/NCBI
40	Inagaki T, Ebisuno S, Uekado Y, Hirano A, Hiroi A, Shinka T and Ohkawa T: PCNA and p53 in urinary bladder cancer: Correlation with histological findings and prognosis. Int J Urol. 4:172–177. 1997. View Article : Google Scholar : PubMed/NCBI
41	Tong Q, Zeng F, Lin C, Zhao J and Lu G: Growth inhibiting effects of antisense eukaryotic expression vector of proliferating cell nuclear antigen gene on human bladder cancer cells. Chin Med J (Engl). 116:1203–1206. 2003.
42	Zhu Z, Xing S, Lin C, Zhang X, Fu M, Liang X, Zeng F, Lu G and Wu M: Bladder cancer therapy using combined proliferating cell nuclear antigen antisense oligonucleotides and recombinant adenovirus p53. Chin Med J (Engl). 116:1860–1863. 2003.
43	Bodó E, Bíró T, Telek A, Czifra G, Griger Z, Tóth BI, Mescalchin A, Ito T, Bettermann A, Kovács L and Paus R: A hot new twist to hair biology: Involvement of vanilloid receptor-1 (VR1/TRPV1) signaling in human hair growth control. Am J Pathol. 166:985–998. 2005. View Article : Google Scholar : PubMed/NCBI
44	de Jong PR, Takahashi N, Harris AR, Lee J, Bertin S, Jeffries J, Jung M, Duong J, Triano AI, Lee J, et al: Ion channel TRPV1-dependent activation of PTP1B suppresses EGFR-associated intestinal tumorigenesis. J Clin Invest. 124:3793–3806. 2014. View Article : Google Scholar : PubMed/NCBI